Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a system-level update with no visible changes to the study details on the page.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedAn administrative revision tag (v3.4.2) was added and previously displayed notices about government funding and operating status were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check38 days agoChange DetectedAdded a government funding lapse notice banner. Updated the page revision tag from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check45 days agoChange DetectedA glossary display option has been added. Labels related to QC status and FEAR Act data were capitalized (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and the revision version updated to v3.4.0.SummaryDifference0.2%

- Check80 days agoChange DetectedAdded a Locations section listing new sites in Arizona, California, Connecticut, Florida, Maryland, Nebraska, New York, Ohio, Pennsylvania, and Tennessee. Removed the individual state location sections and the HHS Vulnerability Disclosure link; updated the revision from v3.3.2 to v3.3.3.SummaryDifference0.9%

- Check102 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.